These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38098548)

  • 1. Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa.
    Khan A; Riaz R; Ashraf S; Akilimali A
    Ann Med Surg (Lond); 2023 Dec; 85(12):6298-6301. PubMed ID: 38098548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB).
    Epstein AL; Haag-Molkenteller C
    Cell; 2023 Aug; 186(17):3523-3523.e1. PubMed ID: 37595560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermolysis bullosa.
    Paller AS; Guide SV; Ayala D; Gonzalez ME; Lucky AW; Bagci IS; Marinkovich MP
    J Dermatolog Treat; 2024 Dec; 35(1):2350232. PubMed ID: 38724041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast-based cell therapy strategy for recessive dystrophic epidermolysis bullosa.
    Yan WF; Murrell DF
    Dermatol Clin; 2010 Apr; 28(2):367-70, xii. PubMed ID: 20447505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa.
    Guide SV; Gonzalez ME; Bağcı IS; Agostini B; Chen H; Feeney G; Steimer M; Kapadia B; Sridhar K; Quesada Sanchez L; Gonzalez F; Van Ligten M; Parry TJ; Chitra S; Kammerman LA; Krishnan S; Marinkovich MP
    N Engl J Med; 2022 Dec; 387(24):2211-2219. PubMed ID: 36516090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of low-dose calcipotriol ointment on wound healing, pruritus and pain in patients with dystrophic epidermolysis bullosa: A randomized, double-blind, placebo-controlled trial.
    Guttmann-Gruber C; Piñón Hofbauer J; Tockner B; Reichl V; Klausegger A; Hofbauer P; Wolkersdorfer M; Tham KC; Lim SS; Common JE; Diem A; Ude-Schoder K; Hitzl W; Lagler F; Reichelt J; Bauer JW; Lang R; Laimer M
    Orphanet J Rare Dis; 2021 Nov; 16(1):473. PubMed ID: 34749770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Collagen VII Expression Is Required in Both Keratinocytes and Fibroblasts for Anchoring Fibril Formation in Bilayer Engineered Skin Substitutes.
    Supp DM; Hahn JM; Combs KA; McFarland KL; Schwentker A; Boissy RE; Boyce ST; Powell HM; Lucky AW
    Cell Transplant; 2019; 28(9-10):1242-1256. PubMed ID: 31271052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal aspects of type VII collagen: Implications for dystrophic epidermolysis bullosa and epidermolysis bullosa acquisita.
    Watanabe M; Natsuga K; Shinkuma S; Shimizu H
    J Dermatol; 2018 May; 45(5):515-521. PubMed ID: 29352483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotaxis-driven disease-site targeting of therapeutic adult stem cells in dystrophic epidermolysis bullosa.
    Alexeev V; Donahue A; Uitto J; Igoucheva O
    Stem Cell Res Ther; 2016 Aug; 7(1):124. PubMed ID: 27568180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rat model for dominant dystrophic epidermolysis bullosa: glycine substitution reduces collagen VII stability and shows gene-dosage effect.
    Nyström A; Buttgereit J; Bader M; Shmidt T; Ozcelik C; Hausser I; Bruckner-Tuderman L; Kern JS
    PLoS One; 2013; 8(5):e64243. PubMed ID: 23717576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Local Concentrations of Intradermal MSCs Restore Skin Integrity and Facilitate Wound Healing in Dystrophic Epidermolysis Bullosa.
    Kühl T; Mezger M; Hausser I; Handgretinger R; Bruckner-Tuderman L; Nyström A
    Mol Ther; 2015 Aug; 23(8):1368-1379. PubMed ID: 25858020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted inactivation of the type VII collagen gene (Col7a1) in mice results in severe blistering phenotype: a model for recessive dystrophic epidermolysis bullosa.
    Heinonen S; Männikkö M; Klement JF; Whitaker-Menezes D; Murphy GF; Uitto J
    J Cell Sci; 1999 Nov; 112 ( Pt 21)():3641-8. PubMed ID: 10523500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients.
    Woodley DT; Cogan J; Hou Y; Lyu C; Marinkovich MP; Keene D; Chen M
    J Clin Invest; 2017 Aug; 127(8):3028-3038. PubMed ID: 28691931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing.
    Woodley DT; Remington J; Huang Y; Hou Y; Li W; Keene DR; Chen M
    Mol Ther; 2007 Mar; 15(3):628-35. PubMed ID: 17245357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural variations in anchoring fibrils in dystrophic epidermolysis bullosa: correlation with type VII collagen expression.
    McGrath JA; Ishida-Yamamoto A; O'Grady A; Leigh IM; Eady RA
    J Invest Dermatol; 1993 Apr; 100(4):366-72. PubMed ID: 8454899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa.
    Wagner JE; Ishida-Yamamoto A; McGrath JA; Hordinsky M; Keene DR; Woodley DT; Chen M; Riddle MJ; Osborn MJ; Lund T; Dolan M; Blazar BR; Tolar J
    N Engl J Med; 2010 Aug; 363(7):629-39. PubMed ID: 20818854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case Report: Diagnostic and Therapeutic Challenges in Severe Mechanobullous Epidermolysis Bullosa Acquisita.
    Schauer F; Nyström A; Kunz M; Hübner S; Scholl S; Athanasiou I; Alter S; Fischer J; Has C; Kiritsi D
    Front Immunol; 2022; 13():883967. PubMed ID: 35464429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innovations in the Treatment of Dystrophic Epidermolysis Bullosa (DEB): Current Landscape and Prospects.
    Hou PC; Del Agua N; Lwin SM; Hsu CK; McGrath JA
    Ther Clin Risk Manag; 2023; 19():455-473. PubMed ID: 37337559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblasts show more potential as target cells than keratinocytes in COL7A1 gene therapy of dystrophic epidermolysis bullosa.
    Goto M; Sawamura D; Ito K; Abe M; Nishie W; Sakai K; Shibaki A; Akiyama M; Shimizu H
    J Invest Dermatol; 2006 Apr; 126(4):766-72. PubMed ID: 16439972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restoring type VII collagen in skin.
    Lwin SM; McGrath JA
    Med; 2022 May; 3(5):273-275. PubMed ID: 35584643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.